Spondyloarthritis & psoriatic arthritis
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
Authors' conclusion
Although the analysis was based on a large set of clinical data and the findings were rigorously evaluated, there are some limitations in interpretation due to the study design.
Study context
- Population
- Psoriasis patients in a US electronic health records database
- Participants
- 15,501 patients
- Exposure
- IL-12/23 or IL-23 inhibitors, and IL-17 inhibitors, vs tumour necrosis factor (TNF) inhibitors in psoriasis
- Outcome
- Time to incident inflammatory arthritis
Methodological detailsUS electronic health records database, multivariable regression analysis, Limitations in interpretation due to the study design; prospective clinical trials are missing
- US electronic health records database
- Multivariable regression analysis
- Limitations in interpretation due to the study design; prospective clinical trials are missing
Main finding
As reported in the abstract
Risk of developing inflammatory arthritis
- Significantly lower risk with IL-12/23 or IL-23 inhibitors vs TNF inhibitors
- No significant difference in risk with IL-17 vs TNF inhibitors
- Multivariable regression analysis
Observational data: associations, not effects.
Further findings
Cumulative incidence of psoriatic arthritis (PsA)
- PsA cases per 100 person-years
- 2.6
Original publication
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities. RMD Open. Published 21 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →